Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC).David A. Braun, David Sommerhalder, Marcus Smith Noel et al.|Journal of Clinical Oncology|2025Cited by 1